Background. Hepatitis C virus (HCV) infection is widespread in hemodialysis patients worldwide. Studies of the effectiveness of new generation DAAs in the treatment of HCV infection in hemodialysis patients are limited.We investigated the effectiveness of DAAs in hemodialysis patients with HCV infection.
Background. The impact of alcohol use and HIV infection on receipt of direct-acting antiviral (DAA) therapy and subsequent cure of chronic hepatitis C virus (HCV) is unknown.
Methods. Using the Veterans Health Administration (VA) Birth Cohort (>4.5 million patients born , we performed a cohort study among HCV RNA+ patients with at least one outpatient visit between 1 January 2014 and 31 May 2017; laboratory values were assessed through 30 November 2017. Alcohol use (abstinent, lower risk drinking, hazardous/binge drinking, diagnosis of alcohol use disorder [AUD] ) was assessed in the year prior to the initial outpatient visit based on Alcohol Use Disorders Identification Test-Consumption questionnaire scores and validated ICD AUD codes. We defined DAA receipt based on filled prescriptions and achievement of HCV cure as sustained virologic response ≥12 weeks after treatment (SVR12). We calculated frequency of DAA receipt and SVR12 by alcohol use category and HIV status. We estimated associations between alcohol use and SVR12 by HIV status using logistic regression.
Results. Among 134,491 HCV RNA+ patients with known alcohol use status, 3,670 (3%) were HIV+. More HIV+ patients were dispensed DAA therapy than uninfected persons (53.6% vs. 49.5%; P < 0.0001). Abstinent and lower risk drinkers were more likely to receive DAAs than hazardous/binge drinkers or those with an AUD (52.9%, 51.5%, 47.1%, 44.6%, respectively; P < 0.0001, Figure 1) Figure 2 ). After adjusting for age, FIB-4, BMI, and hepatic decompensation, HIV− patients with an AUD were significantly less likely to achieve SVR12 compared with abstinent patients (OR, 0.88; 95% CI 0.81-0.94, Figure 3) .
Conclusion. HIV+ patients and abstinent or lower risk drinkers were more likely to receive DAAs compared with uninfected patients and hazardous/binge drinkers or those with an AUD. High SVR12 rates were observed across all alcohol categories. These findings indicate a potential role for alcohol interventions along with HCV care and treatment.
Background. Acute hepatitis C (HCV) infection can be sexually transmitted in HIV-infected men who have sex with men (MSM). Since 2014, direct-acting antivirals (DAA) have successfully cured many persons with chronic HCV infection. We examined the incidence of acute HCV infection in HIV-infected persons before and after the widespread use of DAA therapy.
Methods. We used the HIV Atlanta Veterans Affairs Cohort Study (HAVACS) to examine the incident rate (IR) of acute HCV infections during the period of 01 January 2013 to 31 December 2013 (pre-DAA era) and in the post-DAA era (January 1, 2017 to December 31, 2017). Acute HCV infection was identified using HCV seroconversion or HCV viremia with a negative HCV antibody. We also describe the demographic, clinical characteristics, and virologic outcomes of acute HCV infection cases observed since 2014.
Results. In the pre-DAA era, 56 cases of acute HCV were seen among 1,378 persons (IR: 40.6 per 1000). In the post-DAA era, 29 cases were seen among 1,433 persons (IR: 20.2 per 1,000). HAVACS persons seen in 2017 were 52% less likely to be diagnosed with acute HCV infection than those seen in 2013. Of the seven acute HCV cases examined in detail, the median age is 41 years (range 33-60 years). All cases were male and African American race. Two persons had active IV drug use in addition to unprotected anal intercourse as a risk factor for HCV infection. The median CD4 just prior to HCV infection was 753 cells/cm 2 (range: 590-1,046 cells/cm 2 ). One person had a detectable HIV viral load (527 copies/mL) just prior to HCV infection while the other 6 persons had undetectable HIV viral loads. The peak AST ranged from 147 to 1,256 IU/L (median: 798 IU/L) while the peak ALT ranged from 171 to 1,530 IU/L (median: 855 IU/L). The median total bilirubin is 3.5 mg/dL. One person spontaneously cleared his HCV infection, two were treated with DAA therapy, and the other four are under active monitoring.
Conclusion. Acute HCV infections have significantly decreased in HIV-infected persons in the DAA era. However, acute HCV infections can cause severe transaminitis and jaundice. More work is needed to prevent HCV infections in HIV-infected persons.
Disclosures. All authors: No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. Immune checkpoint inhibitors are a novel class of targeted therapy that activates T cell-mediated tumor cell death. Controversies exist about the safety and efficacy of immunotherapy in patients with chronic viral infections affecting T cells, such as hepatitis C virus (HCV). Herein, we analyzed the effect of immune checkpoint inhibitors on HCV viremia and HCV-related hepatic outcome.
Immune Checkpoint Inhibitors in Solid Tumor
Methods. HCV-infected patients with solid tumors seen at MD Anderson Cancer Center (November 2012-April 2018) were enrolled in a prospective observational study. Patients were monitored for the development of HCV reactivation (HCV-RNA ≥1 log 10 IU/mL over baseline), hepatitis flare (alanine transaminase increase to ≥3 times upper limit of normal) and HCV-associated hepatitis (HCV reactivation and hepatitis flare) while on cancer treatment.
Results. Out of 205 chronically infected patients with solid tumors, 12 (6%) received immunotherapy and were seen in the HCV clinic, but only four (2%) returned for regular monitoring (Table 1) . They were followed for 9 months. None of the four patients received concomitant chemotherapy or steroids. Hepatitis flare occurred in three patients, but HCV reactivation or HCV-associated hepatitis was not detected in any study patient. Immune checkpoint inhibitors were discontinued in one patient (25%) due to hepatitis flare unrelated to HCV.
Conclusion. The use of immune checkpoint inhibitors appears to be safe in solid tumor patients with HCV infection. 
